Characteristics of intermediate- and high-risk AML patients in different treatment groups who achieved CR1
| Characteristic . | Chemotherapy (n = 74) . | HRD-HSCT (n = 58) . | P . | ||
|---|---|---|---|---|---|
| No. of patients . | % . | No. of patients . | % . | ||
| Median age, y (range) | 47 (15-60) | 30 (16-47) | < .0001 | ||
| 15-30 | 11 | 14.9 | 30 | 51.7 | |
| 31-60 | 63 | 85.1 | 28 | 48.3 | |
| Sex | |||||
| Female | 41 | 55.4 | 23 | 39.7 | NS |
| Male | 33 | 44.6 | 35 | 60.3 | |
| WBC count, × 109/L (range) | 11.9 (1.0-206.0) | 20.0 (1.3-504.0) | |||
| ≤ 5 | 59 | 79.7 | 45 | 77.6 | NS |
| > 50 | 15 | 20.3 | 13 | 23.4 | |
| FAB type | |||||
| M0 | 0 | 0 | 1 | 1.7 | NS |
| M1 | 4 | 5,1 | 7 | 12.1 | |
| M2 | 52 | 70.5 | 20 | 34.5 | |
| M4 | 8 | 10.3 | 8 | 13.8 | |
| M5 | 9 | 12.8 | 17 | 29.3 | |
| M6 | 1 | 1.3 | 4 | 6.9 | |
| M7 | 0 | 0 | 1 | 1.7 | |
| Risk group | |||||
| Intermediate-risk | 70 | 94.6 | 52 | 89.7 | NS |
| High-risk | 4 | 5.4 | 6 | 10.3 | |
| No. of courses to CR | |||||
| 1 | 43 | 58.1 | 42 | 72.4 | NS |
| 2-3 | 31 | 41.9 | 16 | 27.6 | |
| Comorbidity score* | |||||
| 0 | 39 | NA | 37 | NA | NS |
| 1-2 | 34 | NA | 21 | NA | |
| 3 or higher | 1 | NA | 0 | NA | |
| Characteristic . | Chemotherapy (n = 74) . | HRD-HSCT (n = 58) . | P . | ||
|---|---|---|---|---|---|
| No. of patients . | % . | No. of patients . | % . | ||
| Median age, y (range) | 47 (15-60) | 30 (16-47) | < .0001 | ||
| 15-30 | 11 | 14.9 | 30 | 51.7 | |
| 31-60 | 63 | 85.1 | 28 | 48.3 | |
| Sex | |||||
| Female | 41 | 55.4 | 23 | 39.7 | NS |
| Male | 33 | 44.6 | 35 | 60.3 | |
| WBC count, × 109/L (range) | 11.9 (1.0-206.0) | 20.0 (1.3-504.0) | |||
| ≤ 5 | 59 | 79.7 | 45 | 77.6 | NS |
| > 50 | 15 | 20.3 | 13 | 23.4 | |
| FAB type | |||||
| M0 | 0 | 0 | 1 | 1.7 | NS |
| M1 | 4 | 5,1 | 7 | 12.1 | |
| M2 | 52 | 70.5 | 20 | 34.5 | |
| M4 | 8 | 10.3 | 8 | 13.8 | |
| M5 | 9 | 12.8 | 17 | 29.3 | |
| M6 | 1 | 1.3 | 4 | 6.9 | |
| M7 | 0 | 0 | 1 | 1.7 | |
| Risk group | |||||
| Intermediate-risk | 70 | 94.6 | 52 | 89.7 | NS |
| High-risk | 4 | 5.4 | 6 | 10.3 | |
| No. of courses to CR | |||||
| 1 | 43 | 58.1 | 42 | 72.4 | NS |
| 2-3 | 31 | 41.9 | 16 | 27.6 | |
| Comorbidity score* | |||||
| 0 | 39 | NA | 37 | NA | NS |
| 1-2 | 34 | NA | 21 | NA | |
| 3 or higher | 1 | NA | 0 | NA | |
AML indicates acute myeloid leukemia; CR, complete remission; HRD, haploidentical related donor; HSCT, hematopoietic stem cell transplantation; NS, no significance; WBC, white blood cell; FAB French-American-British; and NA, not available.
According to the Charlson Comorbidity Index.43